ADMA Biologics Inc (NASDAQ:ADMA) hit a new 52-week low on Monday . The stock traded as low as $2.03 and last traded at $2.03, with a volume of 84192 shares trading hands. The stock had previously closed at $2.24.

Separately, ValuEngine downgraded shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

The company has a debt-to-equity ratio of 0.87, a current ratio of 2.83 and a quick ratio of 1.99.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Friday, August 11th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.29). The firm had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $3.52 million. ADMA Biologics had a negative net margin of 35.00% and a negative return on equity of 116.73%. equities research analysts expect that ADMA Biologics Inc will post -2.24 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “ADMA Biologics Inc (ADMA) Hits New 52-Week Low at $2.03” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/08/adma-biologics-inc-adma-hits-new-52-week-low-at-2-03.html.

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Stock Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related stocks with our FREE daily email newsletter.